Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 1, 2004, Pages 161-166

  Calais, Gilles ^a,k   Bardet, Etienne ^b   Sire, Christian ^c   Alfonsi, Marc ^d   Bourhis, Jean ^e   Rhein, Béatrix ^f   Tortochaux, Jacques ^g   Man, Yooye Tao Kong ^h   Auvray, Hugues ⁱ   Garaud, Pascal ^j  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c Centre Hospitalier de Lorient   (France)

^d INSTITUT SAINTE CATHERINE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g CENTRE JEAN PERRIN   (France)

^h Ctr de Radiotherapie J Belot   (France)

ⁱ CENTRE HOSPITALIER   (France)

^j UNIVERSITÉ DE TOURS   (France)

^k CHU BRETONNEAU   (France)

more..

Author keywords

Concomitant chemotherapy; Docetaxel; Oropharynx carcinoma; Radiotherapy

Indexed keywords

CHEMOTHERAPY; DISEASES; PLATINUM; RADIOTHERAPY; SKIN; TOXICITY; TUMORS;

CYTOTOXIC AGENTS;

ONCOLOGY;

DOCETAXEL;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; ERYTHEMA; FEMALE; FRACTIONATION; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OROPHARYNX CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SKIN TOXICITY; STANDARDIZATION; SURVIVAL RATE;

EID: 10744221374     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01370-1     Document Type: Article

References (21)

1. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 91:1999;2081-2086.
2. Brizel D.M., Alsbers M., Fisher S., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 338:1998;1798-1804.
3. Merlano M., Vitale V., Rosso R., et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 327:1992;1115-1121.
4. Adelstein D.J., Saxton J.P., Lavertu P., et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer Preliminary results . Head Neck. 19:1997;567-575.
5. Wendt T.G., Gragenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer A randomized multicenter study . J Clin Oncol. 16:1998;1318-1324.
6. Ringel I., Horwitz S.B. Studies with RP 56976 (Taxotere) A semi synthetic analogue of Taxol . J Natl Cancer Inst. 83:1991;288-291.
7. Geuritte-Voegelein F., Guenard D., Lavelle F., et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem. 34:1991;992-998.
8. Chaffey J.T., Hellman S. Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res. 31:1971;1513-1616.
9. Hennequin C., Giocanti N., Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 56:1996;1842-1850.
10. Glisson B.S., Murphy B.A., Frenette G., et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 20:2002;1593-1599.
11. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 17:1999;3503-3511.
12. Mauer A.M., Masters G.A., Haraf D.J., et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 16:1998;159-164.
13. International Union Against Cancer (UICC). TNM classification of malignant tumours. 4th ed. Hermanek P, Sobin LH, eds. Berlin: Springer; 1987, revised 1992.
14. Dose specification for reporting external beam therapy with photons and electrons. ICRU report 29. Washington, DC: International Commission on Radiation Units and Measurements 1978.
15. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either Cisplatin or Carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck A prospective randomized trial . Radiother Oncol. 43:1997;29-37.
16. Cortes J.E., Pazdur R. Docetaxel. J Clin Oncol. 13:1995;2643-2655.
17. Choy H., Rodriguez F., Koester S. Synergistic effects of Taxol/Taxotere on radiation sensitivity on human tumor cell lines. Int J Radiat Oncol Biol Phys. 4:(Suppl. 1):1993;274-275.
18. Burris H., Irvin R., Kuhn J., et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 11:1993;950-958.
19. Tomiak E., Piccart M.J., Kerger J. A phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 12:1994;1458-1467.
20. Schöffski P., Weihkopf T., Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent Docetaxel . Anticancer Res. 18:1998;4751-4756.
21. Tishler R.B., Norris C.M., Colevas A.D., et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 95:2002;1472-1481.